WP4: Community & Communication: on management, dissemination and patient involvement
Next to monitoring its scientific and clinical ambition, the consortium also aims to develop an outreach program for multiple stakeholders such as patients, students, clinicians and pharmaceutical industry and the general public.
Communication and exchange of knowledge within and beyond the consortium including patients and general public is embedded in this WP, as well as management issues which will also be supported by a patient-advisory board (PAR).
WP5: B-cells in health and disease of B-IMD/B-ONC (merged with WP2)
This WP focuses on the investigation of B-cell differentiation and activation in health and disease over time toidentify common and disease-specific molecular mechanisms involved in the generation and activation of pathogenic B-cells. In this way we will identify biomarkers as common and disease-specific targets with a predictive value to be able to limit or prevent pathogenic B-cell activity and disease.
WP6: Fab glycosylation: structure, function and relevance in B-IMD/B-ONC (merged with WP3)
This WP will focus on the emergence of Fab-glycosylation as a novel, poorly studied layer of antibody and B-cell diversification across diseases . We will study its role in B-cell selection, its significance as a disease-specific diagnostic and prognostic marker, and its physiological functions and effects on antigen-binding over time and the effect of treatment on changes in Fab-glycosylation.
WP7: Effects and efficacy of B-cell targeting in B-IMD/B-ONC
The objective of this WP is to characterize the B-cell (and T-cell) compartment in B-ONC/B-IMD patients before and after therapeutic intervention, using the platform developed in WP2 and WP5, in order to monitor treatment outcome
WP8: Effects and efficacy of antibody removal in B-IMD/B-ONC
The effect of antibody removal by IgG depletion via immunoadsorption columns on B-cells activation, plasmacell development and survival is unclear to date. This highly effective depletion of IgG including autoreactive antibodies may have an effect on immune cell composition and activity – to the point of preventing autoimmune disease from developing. We have recently obtained medical ethical approval to now enable us to study the development of autoantibody and an active B cell derived plasmacell pool in this workpackage, fully integrated with clinical outcome data in various B-IMD and autoantibody-associated B-ONC patient groups.